Primary cutaneous diffuse large B-cell lymphoma, leg type, in a patient with rheumatoid arthritis undergoing etanercept therapy

Mod Rheumatol Case Rep. 2021 Jul;5(2):195-199. doi: 10.1080/24725625.2020.1857008. Epub 2020 Dec 14.

Abstract

An 84-year-old woman, who was diagnosed with rheumatoid arthritis (RA) and was treated with methotrexate and, subsequently, etanercept (ETN) for 6 years, presented with rapidly progressing painful cutaneous mass on the right medial malleolus. The patient was eventually diagnosed with primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT). ETN therapy was promptly discontinued expecting spontaneous regression of the lymphoma, which was thought to have developed as other iatrogenic immunodeficiency-associated lymphoproliferative disorders. However, no tumour regression was noted. Chemoimmunotherapy was subsequently initiated, which resulted in partial remission. PCLBCL-LT rarely occurs in patients with RA. Here, we report the first case of PCLBCL-LT that developed in a patient with RA receiving ETN therapy.

Keywords: Primary cutaneous diffuse large B-cell lymphoma leg type; etanercept; other iatrogenic immunodeficiency-associated lymphoproliferative disorders; rheumatoid arthritis; tumour necrosis factor inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Etanercept* / adverse effects
  • Female
  • Humans
  • Leg / pathology
  • Lymphoma, Large B-Cell, Diffuse* / chemically induced
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Skin Neoplasms* / chemically induced
  • Skin Neoplasms* / diagnosis

Substances

  • Etanercept